Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs

Abstract Background Osimertinib is an irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is the preferred first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC) compared to first-generation EGFR-TKIs. However, limited research...

Full description

Bibliographic Details
Main Authors: Hsu-Yuan Chen, Chia-Hung Chen, Wei-Chih Liao, Yu-Chao Lin, Hung-Jen Chen, Te-Chun Hsia, Wen-Chien Cheng, Chih-Yen Tu
Format: Article
Language:English
Published: BMC 2024-10-01
Series:BMC Pulmonary Medicine
Subjects:
NSCLC
EGFR
Osimertinib
Afatinib
Dacomitinib
Online Access:https://doi.org/10.1186/s12890-024-03336-8

Internet

https://doi.org/10.1186/s12890-024-03336-8

Similar Items